Literature DB >> 17153849

The curiously suspicious: a role for Epstein-Barr virus in lupus.

J B Harley1, I T W Harley, J M Guthridge, J A James.   

Abstract

While the events initiating the development of autoantibodies in systemic lupus erythematosus (SLE) have not yet been convincingly established, newly developed tools for molecular investigation make such an undertaking increasingly practical. Applied to the earliest events in the sequence culminating in lupus autoimmunity, we present a critical potential role for Epstein-Barr virus (EBV) in the development and perhaps perpetuation of SLE. The expected properties for an environmental risk factor for SLE are found in this virus and the human host response against it. Existing data show the molecular progression to autoimmunity observed in SLE patient sera, the discovery of the first autoimmune epitopes in the Sm and Ro autoantigen systems, and the possible emergence of these autoantibodies from the heterologous antibodies against Epstein-Barr nuclear antigen-1 (EBNA-1). Further, existing data demonstrate association of SLE with EBV infection, even preceding the development of autoimmunity. Finally, the data are consistent with a proposed model of lupus pathogenesis that begins with antibodies to EBNA-1, predisposing to immune responses that develop crossreactive autoantibodies that culminate in the development of SLE autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17153849     DOI: 10.1177/0961203306070009

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  40 in total

1.  Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.

Authors:  Daniel Salamon; Monika Adori; Dorina Ujvari; Liang Wu; Lorand L Kis; Harsha S Madapura; Noemi Nagy; George Klein; Eva Klein
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis.

Authors:  Vey Hadinoto; Michael Shapiro; Thomas C Greenough; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

3.  Infection in systemic lupus erythematosus: friend or foe?

Authors:  Lisa Francis; Andras Perl
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

4.  Silica exposure and chronic virus infection synergistically promote lupus-like systemic autoimmunity in mice with low genetic predisposition.

Authors:  Rosana Gonzalez-Quintial; Jessica M Mayeux; Dwight H Kono; Argyrios N Theofilopoulos; Kenneth M Pollard; Roberto Baccala
Journal:  Clin Immunol       Date:  2019-06-05       Impact factor: 3.969

Review 5.  Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.

Authors:  Charles S Via
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

Review 6.  Lupus and Epstein-Barr.

Authors:  Judith A James; Julie M Robertson
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

7.  Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.

Authors:  Julie L Ryan; You-Jun Shen; Douglas R Morgan; Leigh B Thorne; Shannon C Kenney; Ricardo L Dominguez; Margaret L Gulley
Journal:  Dig Dis Sci       Date:  2012-03-13       Impact factor: 3.199

Review 8.  The role of the Epstein-Barr virus in the pathogenesis of some autoimmune disorders - Similarities and differences.

Authors:  G Füst
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-12-23

Review 9.  Idiopathic nephrotic syndrome: the EBV hypothesis.

Authors:  Claire Dossier; Agnès Jamin; Georges Deschênes
Journal:  Pediatr Res       Date:  2016-09-28       Impact factor: 3.756

Review 10.  Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome.

Authors:  Andras Perl
Journal:  Curr Opin Rheumatol       Date:  2009-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.